About Us

Rich Pharmaceuticals, Inc. is a biopharmaceutical company focused on the development of its lead product, RP-323, (12-O- tetradecanoyl- phorbol-13-acetate), for the treatment of acute myelogenous leukemia (AML) in refractory patients. The basis for the interest of the Company to pursue clinical development of TPA in these and possibly other indications is the result of the Prof. Richard Chang.  He has conducted research on TPA for many years and have become an expert in the characteristics of this molecule. Their findings form the scientific basis for the clinical use of TPA. » Read more about us

Latest News

April 4

Rich Pharmaceuticals Retains Contract Research Organization, CMIC, to Manage Upcoming Phase 1/2 Clinical Trial for its Acute Myelocytic Leukemia (AML) and Myelodysplastic Syndrome (MDS) Drug in Thailand View Release

March 30

Rich Pharmaceuticals Further Extends CRO Agreement with Theradex Systems To Manage Upcoming Phase 1/2 Clinical Trial for its Acute Myelocytic Leukemia (AML) and Myelodysplastic Syndrome (MDS) Drug in the United States View Release

February 16

Rich Pharmaceuticals, Inc. Highlights Goals and Objectives for 2016 View Release

» Read Latest News